MedPath

Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-007)

Phase 3
Completed
Conditions
Dry Eye Syndromes
Registration Number
NCT00548301
Lead Sponsor
Sirion Therapeutics, Inc.
Brief Summary

The purpose of this phase 3 study is to determine the safety and efficacy of cyclosporine in the treatment of dry eye syndrome.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Diagnosis of moderate to severe dry eye syndrome with or without Sjogren's syndrome or other autoimmune disease
Exclusion Criteria
  • Intraocular or refractive surgery in the study eye within 3 months prior to study start
  • Unwilling to discontinue use of contact lenses during the run-in and duration of the study
  • Pregnancy or lactation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Eye Center Northeast

🇺🇸

Bangor, Maine, United States

© Copyright 2025. All Rights Reserved by MedPath